StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
SOPH$4.99-1.19%
Fair $4.99+0.0%

SOPH

SOPHiA GENETICS SA

Healthcare / Health Information ServicesNasdaqGS

$4.99

-0.06 (-1.19%)

Fairly Valued+0.0%Fair Value $4.99Fund rank 26/100 · Data gapFallback financials|
SA 27/D
F-Score: 2/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 20%

FCF escenarios

weak_data · normalized FCF $-52.7M · quality 55.0/100

Data gap 26/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 37/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

27/100

D

Piotroski

2/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -1.7%, below the 5% threshold
Thesis & Journal · SOPHLocal privado en este navegador · SOPHiA GENETICS SA
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$358M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-167.6%

↓

Gross Margin

67.4%

↑

Debt/Equity

1.34

↑
52-Week Range$5
$3$6

TradingView lightweight chart

SOPH price, volumen y niveles de valoración

Último $4.990Periodo -70.2%
Fair value: $4.990

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+17.6%

FCF CAGR

—

FCF margin

-57.6%

FCF / Net income

0.56x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $77.3M · net income $-79.0M · FCF $-44.5M

2022-FY → 2025-FY

Gross margin

67.4%+1.7% pts

Operating margin

-91.8%+92.9% pts

Net margin

-102.2%+81.6% pts

FCF margin

-57.6%+111.6% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$77.3M$77.3M$65.2M$62.4M$47.6M
Net Income$-79.0M$-79.0M$-62.5M$-79.0M$-87.4M
EBITDA$-63.4M$-63.4M$-50.8M$-69.6M$-81.4M
EPS-1.17-1.17-0.95-1.22-1.36
Gross Margin67.4%67.4%67.4%68.8%65.7%
Operating Margin-91.8%-91.8%-102.1%-120.0%-184.7%
Net Margin-102.2%-102.2%-95.9%-126.6%-183.9%
Balance Sheet
Debt/Equity1.341.340.310.120.08
Current Ratio2.062.06———
Cash Flow
Free Cash Flow$-44.5M$-44.5M$-52.7M$-62.5M$-80.5M
Returns
ROE-167.6%-167.6%-64.8%-52.2%-43.7%
Valuation
P/B7.157.152.222.200.63
Growth & Yield
Revenue Growth18.6%18.6%4.5%31.1%—
EPS Growth-23.2%-23.2%22.1%10.3%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +66.3%

Total return

+66.3%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.95 → -1.17

Residual

+66.3%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+66.3%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.